MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer

References

• Callahan R, Smith GH. MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways. Oncogene19(8), 992–1001 (2000).
   PubMed Web of Science ®Google Scholar
• Callahan R, Smith GH. Common integration sites for MMTV in viral induced mouse mammary tumors. J. Mammary Gland Biol. Neoplasia13(3), 309–321 (2008).
   PubMed Web of Science ®Google Scholar
• Allred DC, Medina D. The relevance of mouse models to understanding the development and progression of human breast cancer. J. Mammary Gland Biol. Neoplasia13(3), 279–288 (2008).
   PubMed Web of Science ®Google Scholar
• Marcotte R, Muller WJ. Signal transductionin transgenic mouse models of human breast cancer-implications for human breast cancer. J. Mammary Gland Biol. Neoplasia13(3), 323–335 (2008).
   PubMed Web of Science ®Google Scholar
• Vlahakis G, Heston WE, Smith GH. Strain C3H-A-vy-fB mice: ninety percent incidence of mammary tumors transmitted by either parent. Science170(954), 185–187 (1970).
   PubMed Web of Science ®Google Scholar
• Michalides R, Verstraeten R, Shen FW, Hilgers J. Characterization and chromosomal distribution of endogenous mouse mammary tumor viruses of European mouse strains STS/A and GR/A. Virology142(2), 278–290 (1985).
   PubMed Web of Science ®Google Scholar
• Held W, Acha-Orbea H, MacDonald HR, Waanders GA. Superantigens and retroviral infection: insights from mouse mammary tumor virus. Immunol. Today15(4), 184–190 (1994).
   PubMedGoogle Scholar
• Ross SR. Mouse mammary tumor virus and its interaction with the immune system. Immunol. Res.17(102), 209–216 (1998).
   PubMed Web of Science ®Google Scholar
• Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell31(1), 99–109 (1982).
   PubMed Web of Science ®Google Scholar
• Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell2(2), 103–112 (2002).
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Principles of tumor suppression. Cell116(2), 235–246 (2004).
   PubMed Web of Science ®Google Scholar
• Hynes NE, Macdonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell. Biol.21(2), 177–184 (2009).
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J.19(13), 3159–3167 (2000).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235(4785), 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244(4905), 707–712 (1989).
   PubMed Web of Science ®Google Scholar
• Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic and clinical complexities of HER2. Clin. Breast Cancer8(5), 392–401 (2008).
   PubMed Web of Science ®Google Scholar
• Allred DC, Clark GM, Molina R et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum. Pathol.23(9), 974–979 (1992).
   PubMed Web of Science ®Google Scholar
• Mansour EG, Ravdin PM, Dressler L. Prognostic factors in early breast carcinoma. Cancer74(1 Suppl.), 381–400 (1994).
   PubMed Web of Science ®Google Scholar
• Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell45 (5), 649–657 (1986).
   PubMed Web of Science ®Google Scholar
• Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature319(6050), 226–230 (1986).
   PubMed Web of Science ®Google Scholar
• Dankort DL, Muller WJ. Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene19(8), 1038–1044 (2000).
   PubMed Web of Science ®Google Scholar
• Stern DF, Heffernan PA, Weinberg RA. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol. Cell Biol.6(5), 1729–1740 (1986).
   PubMed Web of Science ®Google Scholar
• Xie Y, Li K, Hung MC. Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated neu. Oncogene10(12), 2409–2413 (1995).
   PubMed Web of Science ®Google Scholar
• Kwong KY, Hung MC. A novel splice variant of HER2 with increased transformation activity. Mol. Carcinog.23(2), 62–68 (1998).
   PubMed Web of Science ®Google Scholar
• Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J.18(8), 2149–2164 (1999).
   PubMed Web of Science ®Google Scholar
• Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell54 (1) 105–115 (1988).
   PubMed Web of Science ®Google Scholar
• Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell57(6), 931–936 (1989).
   PubMed Web of Science ®Google Scholar
• Guy CT, Cardiff RD, Muller WJ. Activated neu induces rapid tumor progression. J. Biol. Chem.271(13), 7673–7678 (1996).
   PubMed Web of Science ®Google Scholar
• Siegel PM, Dankort DL, Hardy WR, Muller WJ. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell Biol.14 (11), 7068–7077 (1994).
   PubMed Web of Science ®Google Scholar
• Siegel PM, Muller WJ. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Proc. Natl Acad. Sci. USA93(17), 8878–8883 (1996).
   PubMed Web of Science ®Google Scholar
• Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl Acad. Sci. USA89(22), 10578–10582 (1992).
   PubMed Web of Science ®Google Scholar
• Li B, Rosen JM, McMenamin-Balano J, Muller WJ, Perkins AS. neu/ERBB2 cooperates with p53–172H during mammary tumorigenesis in transgenic mice. Mol. Cell. Biol.17(6), 3155–3163 (1997).
   PubMed Web of Science ®Google Scholar
• D’Amico M, Wu K, Di Vizio D et al. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. Cancer Res.63(12), 3395–3402 (2003).
   PubMed Web of Science ®Google Scholar
• Andrechek ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD, Muller WJ. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc. Natl Acad. Sci. USA97(7), 3444–3449 (2000).
   PubMed Web of Science ®Google Scholar
• Montagna C andrechek ER, Padilla-Nash H, Muller WJ, Ried T. Centrosome abnormalities, recurring deletions of chromosome 4 and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene21(6), 890–898 (2002).
   PubMed Web of Science ®Google Scholar
• Andrechek ER, Laing MA, Girgis-Gabardo AA, Siegel PM, Cardiff RD, Muller WJ. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Res.63(16), 4920–4926 (2003).
   PubMed Web of Science ®Google Scholar
• Fantl V, Edwards PA, Steel JH, Vonderhaar BK, Dickson C. Impaired mammary gland development in Cyl-1(-/-) mice during pregnancy and lactation is epithelial cell autonomous. Dev. Biol.212(1), 1–11 (1999).
   PubMed Web of Science ®Google Scholar
• Sutherland RL, Musgrove EA. Cyclins and breast cancer. J. Mammary Gland Biol. Neoplasia.9(1), 95–104 (2004).
   PubMed Web of Science ®Google Scholar
• Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J. Clin. Oncol.23(18), 4215–4224 (2005).
   PubMed Web of Science ®Google Scholar
• Gillett C, Smith P, Gregory W et al. Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer69(2), 92–99 (1996).
   PubMed Web of Science ®Google Scholar
• Hwang TS, Han HS, Hong YC, Lee HJ, Paik NS. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol. Int.53(2), 74–80 (2003).
   PubMed Web of Science ®Google Scholar
• Bièche I, Olivi M, Noguès C, Vidaud M, Lidereau R. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br. J. Cancer86(4), 580–586 (2002).
   PubMed Web of Science ®Google Scholar
• Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature369(6482), 669–671 (1994).
   PubMed Web of Science ®Google Scholar
• Lin DI, Lessie MD, Gladden AB, Bassing CH, Wagner KU, Diehl JA. Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene27(9), 1231–1242 (2008).
   PubMed Web of Science ®Google Scholar
• Radeva G, Petrocelli T, Behrend E et al. Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J. Biol. Chem.272(21), 13937–13944 (1997).
   PubMed Web of Science ®Google Scholar
• Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature411(6841), 1017–1021 (2001).
   PubMed Web of Science ®Google Scholar
• Yu Q, Sicinska E, Geng Y et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell9(1), 23–32 (2006).
   PubMed Web of Science ®Google Scholar
• Corsino PE, Davis BJ, Nørgaard PH et al. Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component. Neoplasia10(11), 1240–1252 (2008).
   PubMed Web of Science ®Google Scholar
• Ekholm-Reed S, Mendez J, Tedesco D, Zetterberg A, Stillman B, Reed SI. Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J. Cell Biol.165(6), 789–800 (2004).
   PubMed Web of Science ®Google Scholar
• Geng Y, Yu Q, Sicinska E et al. Cyclin E ablation in the mouse. Cell114(4), 431–443 (2003).
   PubMed Web of Science ®Google Scholar
• Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature401(6750), 297–300 (1999).
   PubMed Web of Science ®Google Scholar
• Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol. Cell. Biol.17(1), 453–459 (1997).
   PubMed Web of Science ®Google Scholar
• Akli S, Zheng PJ, Multani AS et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27 and antiestrogens in breast cancer. Cancer Res.64(9), 3198–3208 (2004).
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc. Natl Acad. Sci USA90(3), 1112–1116 (1993).
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, O’Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res.54(2), 380–385 (1994).
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Conte D Jr, Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene11(5), 941–950 (1995).
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Tucker SL, Buchholz TA et al. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med.347(20), 1566–1575 (2002).
   PubMed Web of Science ®Google Scholar
• Akli S, Van Pelt CS, Bui T et al. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res.67(15), 7212–7222 (2007).
   PubMed Web of Science ®Google Scholar
• Bos JL. ras oncogenes in human cancer: a review. Cancer Res.49(17), 4682–4689, (1989).
   PubMed Web of Science ®Google Scholar
• McCormick F. Signal transduction. How receptors turn Ras on. Nature363(6424), 15–16, (1993).
   PubMed Web of Science ®Google Scholar
• Downward J. Cell cycle: routine role for Ras. Curr Biol.7(4), R258–260 (1997).
   PubMed Web of Science ®Google Scholar
• Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biother.1(6), 599–606 (2002).
   Google Scholar
• Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F. Cancer targets in the Ras pathway. Cold Spring Harb. Symp. Quant. Biol.70, 461–467 (2005).
   PubMedGoogle Scholar
• Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell49(4), 465–475 (1987).
   PubMed Web of Science ®Google Scholar
• Hundley JE, Koester SK, Troyer DA, Hilsenbeck SG, Subler MA, Windle JJ. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol. Cell. Biol.17(2), 723–731 (1997).
   PubMed Web of Science ®Google Scholar
• Donehower LA, Harvey M, Slagle BL et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature356(6366), 215–221 (1992).
   PubMed Web of Science ®Google Scholar
• Adnane J, Jackson RJ, Nicosia SV, Cantor AB, Pledger WJ, Sebti SM. Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene19(47), 5338–5347 (2000).
   PubMed Web of Science ®Google Scholar
• Missero C, Di Cunto F, Kiyokawa H, Koff A, Dotto GP. The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev.10(23), 3065–3075 (1996).
   PubMed Web of Science ®Google Scholar
• Bearss DJ, Lee RJ, Troyer DA, Pestell RG, Windle JJ. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties. Cancer Res.62(7), 2077–2084 (2002).
   PubMed Web of Science ®Google Scholar
• Amati B, Frank SR, Donjerkovic D, Taubert S. Function of the c-Myc oncoprotein in chromatin remodeling and transcription. Biochim. Biophys. Acta1471(3), M135–145 (2001).
   PubMedGoogle Scholar
• Eisenman RN. Deconstructing myc. Genes Dev.15(16), 2023–2030 (2001).
   PubMed Web of Science ®Google Scholar
• Takayama M, Taira T, Iguchi-Ariga SM, Ariga H. CDC6 interacts with c-Myc to inhibit E-box-dependent transcription by abrogating c-Myc/Max complex. FEBS Lett.477(1–2), 43–48 (2000).
   PubMed Web of Science ®Google Scholar
• Al-Kuraya K, Schraml P, Torhorst J et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res.64(23), 8534–8540 (2004).
   PubMed Web of Science ®Google Scholar
• Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell38(3), 627–637 (1984).
   PubMed Web of Science ®Google Scholar
• Schoenenberger CA andres AC, Groner B, van der Valk M, LeMeur M, Gerlinger P. Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. EMBO J.7(1), 169–175 (1988).
   PubMed Web of Science ®Google Scholar
• Soengas MS, Alarcón RM, Yoshida H et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science284(5411), 156–159 (1999).
   PubMed Web of Science ®Google Scholar
• Coldwell MJ, Mitchell SA, Stoneley M, MacFarlane M, Willis AE. Initiation of Apaf-1 translation by internal ribosome entry. Oncogene19(7), 899–905 (2000).
   PubMed Web of Science ®Google Scholar
• Ray D, Terao Y, Fuhrken PG et al. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res.67(3), 984–991 (2007).
   PubMed Web of Science ®Google Scholar
• Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature382(6591), 511–517 (1996).
   PubMed Web of Science ®Google Scholar
• LaBaer J, Garrett MD, Stevenson LF et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev.11(7), 847–862 (1997).
   PubMed Web of Science ®Google Scholar
• Cheng M, Olivier P, Diehl JA et al. The p21(Cip1) and p27(Kip1) CDK ‘inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J.18(6), 1571–1583 (1999).
   PubMed Web of Science ®Google Scholar
• McCormack SJ, Weaver Z, Deming S et al. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene16(21), 2755–2766 (1998).
   PubMed Web of Science ®Google Scholar
• Katoh M. WNT and FGF gene clusters (review). Int. J. Oncol.21(6), 1269–1273 (2002).
   PubMed Web of Science ®Google Scholar
• Clevers H. Wnt/β-catenin signaling in development and disease. Cell127(3), 469–480 (2006).
   PubMed Web of Science ®Google Scholar
• Chien AJ, Conrad WH, Moon RT. A Wnt survival guide: from flies to human disease. J. Invest. Dermatol.129(7), 1614–1627 (2009).
   PubMed Web of Science ®Google Scholar
• Nusse R. The int genes in mammary tumorigenesis and in normal development. Trends Genet.4(10), 291–295 (1988).
   PubMed Web of Science ®Google Scholar
• Dickson C, Fantl V. Fgf-3, an oncogene in murine breast cancer. Cancer Treat. Res.71, 331–343 (1994).
   PubMedGoogle Scholar
• Howe LR, Brown AMC. Wnt signaling and breast cancer. Cancer Biol. Ther3(1), 36–41 (2004).
   PubMed Web of Science ®Google Scholar
• Klarmann GJ, Decker A, Farrar WL. Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics3(2), 59–63 (2008).
   PubMed Web of Science ®Google Scholar
• Lin SY, Xia W, Wang JC et al. β-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl Acad. Sci. USA97(8), 4262–4266 (2000).
   PubMed Web of Science ®Google Scholar
• Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. Pin1 regulates turnover and subcellular localization of β-catenin by inhibiting its interaction with APC. Nat. Cell Biol.3(9), 793–801 (2001).
   PubMed Web of Science ®Google Scholar
• Nusse R, van Ooyen A, Cox D, Fung YK, Varmus H. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature307(5947), 131–136 (1984).
   PubMed Web of Science ®Google Scholar
• Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell55(4), 619–625 (1988).
   PubMed Web of Science ®Google Scholar
• Shackleford GM, MacArthur CA, Kwan HC, Varmus HE. Mouse mammary tumor virus infection accelerates mammary carcinogenesis in Wnt1 transgenic mice by insertional activation of int-2/Fgf-3 and hst/Fgf-4. Proc. Natl Acad. Sci. USA90(2), 740–744 (1993).
   PubMed Web of Science ®Google Scholar
• Donehower LA, Godley LA, Aldaz CM et al. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev.9(7), 882–895 (1995).
   PubMed Web of Science ®Google Scholar
• Rowlands TM, Pechenkina IV, Hatsell SJ, Pestell RG, Cowin P. Dissecting the roles of β-catenin and cyclin D1 during mammary development and neoplasia. Proc. Natl Acad. Sci. USA100(20), 11400–11405 (2003).
   PubMed Web of Science ®Google Scholar
• Jhappan C, Gallahan D, Stahle C et al. Expression of an activated Notch-Related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev.6(3), 345–355 (1992).
   PubMed Web of Science ®Google Scholar
• Callahan R, Raafat A. Notch signaling in mammary gland tumorigenesis. J. Mammary Gland Biol. Neoplasia6(1), 23–36 (2001).
   PubMed Web of Science ®Google Scholar
• Shi W, Harris AL. Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J. Mammary Gland Biol. Neoplasia11(1), 41–52 (2006).
   PubMed Web of Science ®Google Scholar
• Sovak MA, Arsura M, Zanieski G, Kavanagh KT, Sonenshein GE. The inhibitory effects of transforming growth factor beta1 on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor-κB/Rel expression. Cell Growth Differ.10(8), 537–544 (1999).
   PubMedGoogle Scholar
• Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr. Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3. Oncogene19(9), 1123–1131 (2000).
   PubMed Web of Science ®Google Scholar
• Romieu-Mourez R, Kim DW, Shin SM et al. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol. Cell. Biol.23(16), 5738–5754 (2003).
   PubMed Web of Science ®Google Scholar
• Shin SR, Sánchez-Velar N, Sherr DH, Sonenshein GE. 7,12-dimethylbenz(a)anthracene treatment of a c-rel mouse mammary tumor cell line induces epithelial to mesenchymal transition via activation of nuclear factor-κB. Cancer Res.66(5), 2570–2575 (2006).
   PubMed Web of Science ®Google Scholar
• Gunther EJ, Belka GK, Wertheim GB et al. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J.16(3), 283–292 (2002).
   PubMed Web of Science ®Google Scholar
• Moody SE, Sarkisian CJ, Hahn KT et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell2(6), 451–461 (2002).
   PubMed Web of Science ®Google Scholar
• Gunther EJ, Moody SE, Belka GK et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev.17(4), 488–501 (2003).
   PubMed Web of Science ®Google Scholar
• Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat. Cell Biol.9(5), 493–505 (2007).
   PubMed Web of Science ®Google Scholar
• Davie SA, Maglione JE, Manner CK et al. Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res.16(2), 193–201 (2007).
   PubMed Web of Science ®Google Scholar
• Mahler JF, Stokes W, MannPC, Takaoka M, Maronpot RR. Spontaneous lesions in aging FVB/N mice. Toxicol. Pathol.24(6), 710–716 (1996).
   PubMed Web of Science ®Google Scholar
• Rowse GJ, Ritland SR, Gendler SJ. Genetic Modulation of neu proto-oncogene-induced mammary tumorigenesis. Cancer Res.58(12), 2675–2679 (1998).
   PubMed Web of Science ®Google Scholar
• Mikaelian I, Blades N, Churchill GA et al. Proteotypic classification of spontaneous and transgenic mammary neoplasms. Breast Cancer Res.6(6), R668–R679 (2004).
   Google Scholar
• Durgam VR, Tekmal RR. The nature and expression of int-5, a novel MMTV integration locus gene in carcinogen-induced mammary tumors. Cancer Lett.87(2), 179–186 (1994).
   PubMed Web of Science ®Google Scholar
• Bui TD, Rankin J, Smith K et al. A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas. Oncogene14(10), 1249–1253 (1997).
   PubMed Web of Science ®Google Scholar
• Theodorou V, Kimm MA, Boer M et al. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat. Genet.39(6), 759–769 (2007).
   PubMed Web of Science ®Google Scholar
• Axel R, Schlom J, Spiegelman S. Presence in human breast cancer of RNA homologous to mouse mammary tumour virus RNA. Nature235(5332), 32–36 (1972).
   PubMed Web of Science ®Google Scholar
• Levine PH, Mesa-Tejada R, Keydar I, Tabbane F, Spiegelman S, Mourali N. Increased incidence of mouse mammary tumor virus-related antigen in Tunisian patients with breast cancer. Int. J. Cancer33(3), 305–308 (1984).
   PubMed Web of Science ®Google Scholar
• Litvinov SV, Golovkina TV. Expression of proteins immunologically related to murine mammary tumour virus (MMTV) core proteins in the cells of breast cancer continuous lines MCF-7, T47D, MDA-231 and cells from human milk. Acta Virol.33(2), 137–142 (1989).
   PubMed Web of Science ®Google Scholar
• Zotter S, Kemmer C, Lossnitzer A, Grossmann H, Johannsen BA. Mouse mammary tumour virus-related antigens in core-like density fractions from large samples of women’s milk. Eur. J. Cancer16(4), 455–467 (1980).
   Web of Science ®Google Scholar
• Day NK, Witkin SS, Sarkar NH et al. Antibodies reactive with murine mammary tumor virus in sera of patients with breast cancer: geographic and family studies. Proc. Natl Acad. Sci. USA78(4), 2483–2487 (1981).
   PubMed Web of Science ®Google Scholar
• Witkin SS, Sarkar NH, Kinne DW, Breed CN, Good RA, Day NK. Antigens and antibodies cross-reactive to the murine mammary tumor virus in human breast cyst fluids. J. Clin. Invest.67(1), 216–222 (1981).
   PubMed Web of Science ®Google Scholar
• Keydar I, Ohno T, Nayak R et al. Properties of retrovirus-like particles produced by a human breast carcinoma cell line: immunological relationship with mouse mammary tumor virus proteins. Proc. Natl Acad. Sci. USA81(13), 4188–4192 (1984).
   PubMed Web of Science ®Google Scholar
• Wang Y, Holland JF, Bleiweiss IJ et al. Detection of mammary tumor virus env gene-like sequences in human breast cancer. Cancer Res.55(22), 5173–5179 (1995).
   PubMed Web of Science ®Google Scholar
• Etkind P, Du J, Khan A, Pillitteri J, Wiernik PH. Mouse mammary tumor virus-like ENV gene sequences in human breast tumors and in a lymphoma of a breast cancer patient. Clin. Cancer Res.6(4), 1273–1278 (2000).
   PubMed Web of Science ®Google Scholar
• Amarante MK, Watanabe MA. The possible involvement of virus in breast cancer. J. Cancer Res. Clin. Oncol.135(3), 329–337 (2009).
   PubMed Web of Science ®Google Scholar
• Zammarchi F, Pistello M, Piersigilli A et al. MMTV-like sequences in human breast cancer: a fluorescent PCR/laser microdissection approach. J. Pathol.209(4), 436–444 (2006).
   PubMed Web of Science ®Google Scholar
• Liu B, Wang Y, Melana SM et al. Identification of a proviral structure in human breast cancer. Cancer Res.61(4), 1754–1759 (2001).
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang JD, Xu D et al. A mouse mammary tumor virus-like long terminal repeat superantigen in human breast cancer. Cancer Res.64(12), 4105–4111 (2004).
   PubMed Web of Science ®Google Scholar
• Lawson JS, Tran DD, Carpenter E et al. Presence of mouse mammary tumour-like virus gene sequences may be associated with morphology of specific human breast cancer. J. Clin. Pathol.59(12), 1287–1292 (2006).
   PubMed Web of Science ®Google Scholar
• Etkind PR, Stewart AF, Wiernik PH. Mouse mammary tumor virus (MMTV)-like DNA sequences in the breast tumors of father, mother and daughter. Infect. Agent. Cancer3(2), 1–11 (2008).
   PubMedGoogle Scholar
• Wang Y, Melana SM, Baker B et al. High prevalence of MMTV-like env gene sequences in gestational breast cancer. Med. Oncol.20(3), 233–236 (2003).
   PubMed Web of Science ®Google Scholar
• Faedo M, Ford CE, Mehta R, Blazek K, Rawlinson WD. Mouse mammary tumor-like virus is associated with p53 nuclear accumulation and progesterone receptor positivity but not estrogen positivity in human female breast cancer. Clin. Cancer Res.10(13), 4417–4419 (2004).
   PubMed Web of Science ®Google Scholar
• Langerød A, Zhao H, Borgan Ø et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res.9(3), R30 (2007).
   PubMed Web of Science ®Google Scholar
• Ford CE, Faedo M, Crouch R, Lawson JS, Rawlinson WD. Progression from normal breast pathology to breast cancer is associated with increasing prevalence of mouse mammary tumor virus-like sequences in men and women. Cancer Res.64(14), 4755–4759 (2004).
   PubMed Web of Science ®Google Scholar
• Witkin SS, Sarkar NH, Kinne DW, Good RA, Day NK. Antibodies reactive with the mouse mammary tumor virus in sera of breast cancer patients. Int. J. Cancer25(6), 721–725 (1980).
   PubMed Web of Science ®Google Scholar
• Tomana M, Kajdos AH, Niedermeier W, Durkin WJ, Mestecky J. Antibodies to mouse mammary tumor virus-related antigen in sera of patients with breast carcinoma. Cancer47(11), 2696–2703 (1981).
   PubMed Web of Science ®Google Scholar
• Keydar I, Selzer G, Chaitchik S, Hareuveni M, Karby S, Hizi A. A viral antigen as a marker for the prognosis of human breast cancer. Eur. J. Cancer Clin. Oncol.18(12), 1321–1328 (1982).
   PubMedGoogle Scholar
• Chaitchik S, Kabakow B, De Chabon A et al. Prognostic factors in breast cancer – a pathological and immunological study of patients with stage 1 breast cancer. Eur. J. Surg. Oncol.13(6), 499–504 (1987).
   PubMedGoogle Scholar
• Tilli MT, Frech MS, Steed ME et al. Introduction of estrogen receptor-α into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am. J. Pathol.163(5), 1713–1719 (2003).
   PubMed Web of Science ®Google Scholar
• Wagner KU, Wall RJ, St-Onge L et al. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res.25(21), 4323–4330 (1997).
   PubMed Web of Science ®Google Scholar
• Dourdin N, Schade B, Lesurf R et al. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res.68(7), 2122–2131 (2008).
   PubMed Web of Science ®Google Scholar
• Roussel MF, Theodoras AM, Pagano M, Sherr CJ. Rescue of defective mitogenic signaling by D-type cyclins. Proc. Natl Acad. Sci. USA92(15), 6837–6841 (1995).
   PubMed Web of Science ®Google Scholar
• Inoue K, Roussel MF, Sherr CJ. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc. Natl Acad. Sci. USA96(7), 3993–3998 (1999).
   PubMed Web of Science ®Google Scholar
• Inoue K, Wen R, Rehg JE et al. (2000). Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation and tumorigenesis. Genes Dev.14(14), 1797–1809 (2000).
   PubMed Web of Science ®Google Scholar
• Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev.15(22), 2934–2939 (2001).
   PubMed Web of Science ®Google Scholar
• Inoue K, Mallakin A, Frazier, DP. Dmp1 and tumor suppression (Review). Oncogene26(30), 4329–4335 (2007).
   PubMed Web of Science ®Google Scholar
• Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ, Inoue K. Ras-Raf-Arf signaling critically depends on Dmp1 transcription factor. Mol. Cell. Biol.25(1), 220–232 (2005).
   PubMed Web of Science ®Google Scholar
• Mallakin A, Taneja P, Matise LA, Willingham MC, Inoue K. Expression of Dmp1 in specific differentiated, nonproliferating cells and its repression by E2Fs. Oncogene25(59), 7703–7713 (2006).
   PubMed Web of Science ®Google Scholar
• Taneja P, Mallakin, A, Matise LA, Frazier DP, Choudhary M, Inoue K. Repression of Dmp1 and Arf transcription by anthracyclins: critical roles of the NF-κB subunit p65. Oncogene26(33), 7457–7466 (2007).
   PubMed Web of Science ®Google Scholar
• Mallakin A, Sugiyama T, Taneja P et al. Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell12(4), 381–394 (2007).
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Taneja P, Frazier DP et al. Oncogenic and non-oncogenic signaling pathways that regulate Dmp1 (Dmtf1). Clin. Med. Oncol.2, 1–11 (2008).
   PubMedGoogle Scholar
• Sugiyama T, Frazier DP, Taneja P, Morgan RL, Willingham MC, Inoue K. Role of DMP1 and its future in lung cancer diagnostics. Expert Rev. Mol. Diagn.8(4), 435–447 (2008).
   PubMed Web of Science ®Google Scholar